A retrospective study of the management of vulvodynia

Korean Journal of Urology

Volumn 54, Issue 1, 2013, Pages 48-52

  Jeon, Yongseok ^a   Kim, Youngjun ^a   Shim, Bosun ^a   Yoon, Hana ^a   Park, Youngyo ^a   Shim, Bongsuk ^a   Jeong, Woosik ^a   Lee, Donghyun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Dyspareunia; Gabapentin; Type A botulinum toxins; Vulvodynia

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; NAUSEA; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEXUAL DYSFUNCTION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VULVODYNIA;

EID: 84874364899     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2013.54.1.48     Document Type: Article

References (25)

1. McKay M. Vulvodynia. A multifactorial clinical problem. Arch Dermatol 1989;125:256-62.
2. International Society for the Study of Vulvar Disease Taskforce. Burning vulvar syndrome: report of the ISSVD taskforce. J Reprod Med 1984;29:457.
3. Lotery HE, McClure N, Galask RP. Vulvodynia. Lancet 2004; 363:1058-60.
4. Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res 2007;19:84-7.
5. Bergeron S, Binik YM, Khalife S, Meana M, Berkley KJ, Pagidas K. Treatment of vulvar vestibulitis syndrome: toward a mutilmodal approach. Sex Marital Ther 1997;12:305-11.
6. Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of gabapentin. J Pharmacol Sci 2006;100:471-86.
7. McKay M. Subsets of vulvodynia. J Reprod Med 1988;33:695-8.
8. van Lankveld JJ, Granot M, Weijmar Schultz WC, Binik YM, Wesselmann U, Pukall CF, et al. Women's sexual pain disorders. J Sex Med 2010;7(1 Pt 2):615-31.
9. Steers WD, Tuttle JB. Neurogenic inflammation and nerve growth factor: possible roles in interstitial cystitis. In: Sant GR, editor. Interstitial cystitis. Philadelphia: Lippincott-Raven Publishers; 1997. p. 67-75.
10. Wesselmann U. Neurogenic inflammation and chronic pelvic pain. World J Urol 2001;19:180-5.
11. Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol 2008;112:579-85.
12. Ventolini G, Barhan S, Duke J. Vulvodynia, a step-wise therapeutic prospective cohort study. J Obstet Gynaecol 2009;29: 648-50.
13. Harris G, Horowitz B, Borgida A. Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked. J Reprod Med 2007;52:103-6.
14. Ben-David B, Friedman M. Gabapentin therapy for vulvodynia. Anesth Analg 1999;89:1459-60.
15. Yoshimura N, de Groat WC. Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J Neurosci 1999;19:4644-53.
16. Fitzgerald MP, Koch D, Senka J. Visceral and cutaneous sensory testing in patients with painful bladder syndrome. Neurourol Urodyn 2005;24:627-32.
17. Ness TJ, Crimaldi JC, McDanal JT. Case report on gabapentin. Reg Anesth Pain Med 1998;23:110-1.
18. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986;26:427-53.
19. Angaut-Petit D, Molgo J, Comella JX, Faille L, Tabti N. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 1990;37:799-808.
20. Naumann M, Jost WH, Toyka KV. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol 1999;56:914-6.
21. Gottsch HP, Yang CC, Berger RE. A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scand J Urol Nephrol 2011;45:72-6.
22. Gottsch HP, Yang CC, Berger RE. A review of botulinum toxin use for chronic pelvic pain syndrome. Curr Urol Rep 2010;11:265-70.
23. Giannantoni A, Cagini R, Del Zingaro M, Proietti S, Quartesan R, Porena M, et al. Botulinum A toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and Quality of Life. Curr Drug Deliv 2010;7:442-6.
24. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med 2009;6:2523-37.
25. Pelletier F, Parratte B, Penz S, Moreno JP, Aubin F, Humbert P. Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol 2011;164:617-22.